new ceo is interviewing existing vice-presidents to see who would stay and who has to go. This is under pretext to introduce himself and know them better. Considerations for external candidates are already in place.
Good performers after being hired are formed using the Roche mold and after a few years they become average or worse.
They will take this new normal with them when they change employment.
With closing manufacturing the company has become a large aimless research place following the requests from Roche. Its executives are unable to make independent decisions
Lost connection to manufacturing. The management decided to close the manufacturing plants. It has become a place doing often irrelevant work for the parent company. It has been also a source of personnel for smaller companies with disappointing results. These people taken out of their niches lack perspective of broad aspects of drug development process.